StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research note published on Monday. The firm issued a sell rating on the stock.
Separately, Maxim Group cut shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th.
Get Our Latest Research Report on Moleculin Biotech
Moleculin Biotech Stock Performance
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Featured Articles
- Five stocks we like better than Moleculin Biotech
- What is a Dividend King?
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- What is the Euro STOXX 50 Index?
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
